Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Pharma’s path to Net Zero

Posted on May 3rd, 2022 by

Pharma R&D

Pharma is seldom top of mind when thinking about the most polluting industries, but pharmaceutical industry operations are in fact responsible for a significant portion of the world’s greenhouse gas emissions – even rivaling industries that are far more associated with contributing to the problem. 

(more…)

Elsevier and LG: Turning data into action

Posted on April 28th, 2022 by

AI & Data

There are life-changing insights waiting to be found in chemistry data. The critical information waiting to be unlocked can lead to incredible technology advances and medical breakthroughs. But there is so much data out there, and it is multiplying rapidly. At Elsevier, we are excited about a new partnership with world-renowned innovator LG that we are confident will enable researchers to discover and surface more relevant chemistry facts and relationships from scientific literature than ever before.

(more…)

Pharma can now track the most relevant patent info – fast and at scale

Posted on April 26th, 2022 by

AI & Data

Since its initial release in January 2021, AI-fueled Patent Expansion in Reaxys has won the respect of pharmaceutical companies trying to stay ahead of their competitors by keeping track of the latest patents around drug discovery and new therapeutics. With a recent expansion that allows Reaxys to also loop in information from images found in patents, it’s a good time to look back – and forward – at this continual work-in-progress. We spoke to Umesh Nandal, Elsevier’s Director of Data Science, about the logic behind the tech: “It’s not just about the speed of access to all this annotated data, but the quality.”

(more…)

Elsevier research partner Karin Verspoor nominated for Women in AI award

Posted on April 5th, 2022 by

AI & Data

Network

In recognition of her numerous research accomplishments, Professor Karin Verspoor is nominated for the prestigious Women in AI Award under the ‘AI in Innovation’ category. Certainly, the interdisciplinary work she has undertaken with Elsevier has chemists and pharmaceutical companies excited about the real-world impact of automating the extraction of chemical reaction information from patents.

(more…)

How publishing can help address diversity in STEM

Posted on March 30th, 2022 by

Pharma R&D

The issue of diversity in science, technology, engineering and mathematics is not a new topic, but it is one that needs to be continually addressed as these sectors endeavor to be more inclusive. And it is possible that publishing, an area that itself has work to do in diversity, could provide some metrics to help confront the diversity deficit.

(more…)

Umesh Nandal: Chemist and data scientist in one

Posted on March 10th, 2022 by

AI & Data

Umesh Nandal is a Director of Data Science at Elsevier. As an AI expert with a Master’s in Chemistry, he embodies what Elsevier brings to the table – an actionable fusion of data and domain expertise. “Cross-functional teams combining data science, tech and domain knowledge is the only way we can achieve our collective goal: curing disease,” says Umesh.

(more…)

  1. 1
  2. 2
  3. 3
  4. 88

About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.